Abstract | BACKGROUND:
Crofelemer improves bowel function in several conditions characterized by states of prominent secretory diarrhea. AIM: METHODS: Male and female patients were randomly assigned to receive crofelemer 125, 250 or 500 mg or placebo twice daily for 12 weeks. The primary efficacy measure was a responder for improvement in stool consistency. In addition, abdominal pain- and discomfort-free days, pain and discomfort scores as well as other bowel function parameters (such as stool frequency and consistency, urgency, bloating) were evaluated. RESULTS: Two hundred and forty-two D-IBS patients were randomized. Crofelemer did not produce significant improvement in stool consistency (primary endpoint), stool frequency, urgency or adequate relief. However, female D-IBS patients showed improvement in the proportion of pain- and discomfort-free days during treatment with 500 mg crofelemer: month 1 ( crofelemer vs. placebo: 17.7 vs. 10.2%, p = 0.098); month 2 (23.5 vs. 13.3%, p = 0.076); month 3 (26.1 vs. 10.6%, p = 0.0076). No benefit was seen in male D-IBS patients. Crofelemer was well tolerated. CONCLUSIONS: Crofelelmer did not produce benefit on bowel function; an increase in the number of pain- and discomfort-free days in female D-IBS patients was seen. Further studies with crofelemer are warranted to evaluate it as a potential visceral analgesic.
|
Authors | Allen W Mangel, Pravin Chaturvedi |
Journal | Digestion
(Digestion)
Vol. 78
Issue 4
Pg. 180-6
( 2008)
ISSN: 1421-9867 [Electronic] Switzerland |
PMID | 19092244
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Plant Extracts
- Proanthocyanidins
- crofelemer
|
Topics |
- Adult
- Croton
(chemistry)
- Diarrhea
(etiology)
- Double-Blind Method
- Female
- Gastrointestinal Diseases
(chemically induced)
- Humans
- Irritable Bowel Syndrome
(complications, drug therapy)
- Male
- Middle Aged
- Pain
(etiology, physiopathology)
- Plant Extracts
(adverse effects, therapeutic use)
- Proanthocyanidins
(adverse effects, therapeutic use)
- Sex Factors
- Treatment Outcome
|